C. Cruz

发表

CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo

J. Rodgers, D. Douek, P. Hanley, 2015, Science Translational Medicine.

The growth hormone secretagogue receptor.

C. Cruz, Roy G. Smith, 2008, Vitamins and hormones.

Directed T-cell therapies for leukemia and lymphoma after hematopoietic stem cell transplant: beyond chimeric antigen receptors

C. Cruz, C. Bollard, A. Barrett, 2015 .

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

U. Gerdemann, C. Cruz, H. Heslop, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.

P. Hanley, C. Cruz, Hao Liu, 2010, Cytotherapy.

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

Y. Zu, C. Cruz, Hao Liu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.

C. Cruz, C. Bollard, 2017, Current drug targets.

A closer look at chimeric antigen receptor specificity.

C. Cruz, 2014, Cytotherapy.

Differential Expression of Wilms’ Tumor Protein in Diffuse Intrinsic Pontine Glioma

C. Cruz, S. Yadavilli, R. Packer, 2019, Journal of neuropathology and experimental neurology.

Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer

E. V. Van Allen, Song Liu, S. Lipkin, 2020, Journal for immunotherapy of cancer.

The growth hormone secretagogue receptor.

C. Cruz, Roy G. Smith, 2008, Vitamins and hormones.

Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.

C. Cruz, C. Bollard, M. Long, 2022, Cytotherapy.

Low rate of infusional toxicity after expanded cord blood transplantation.

K. Rezvani, P. Hanley, C. Cruz, 2014, Cytotherapy.

Low Rate of Infusional Toxicity following Expanded Cord Blood Transplantation

H. Liu, K. Rezvani, P. Hanley, 2014 .

HIV Receives a "One Two Knockout Punch".

C. Cruz, C. Bollard, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Post‐transplant lymphoproliferative disorders

C. Cruz, C. Bollard, M. Keller, 2017 .

Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization

P. Hanley, C. Cruz, C. Bollard, 2019, Journal of Translational Medicine.

Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.

P. Hanley, C. Cruz, Hao Liu, 2009, Blood.

Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy

P. Hanley, C. Cruz, S. Lam, 2013, Clinical and experimental immunology.

Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β

Christopher A. Lazarski, C. Cruz, C. Bollard, 2022, Molecular therapy. Methods & clinical development.

Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes.

P. Hanley, C. Cruz, C. Bollard, 2016, Cytotherapy.

Functionally Active HIV-specific T cells that Target gag and nef can be expanded from Virus-naive Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT

C. Cruz, S. Lam, C. Bollard, 2016 .

Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

C. Cruz, S. Lam, C. Rooney, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Gene-modified, cell-based therapies-an overview.

C. Cruz, Allison B. Powell, Kiara Williams, 2016, Cytotherapy.

Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

P. Hanley, C. Cruz, E. Shpall, 2010, Cytotherapy.

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

C. Cruz, S. Lam, R. Krance, 2013, Blood.

Cord blood natural killer cells expressing a dominant negative TGF-β receptor: Implications for adoptive immunotherapy for glioblastoma.

C. Cruz, C. Bollard, E. Yvon, 2017, Cytotherapy.

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

P. Hanley, C. Cruz, R. Krance, 2009, Blood.

Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells

R. Siliciano, B. Walker, D. Nixon, 2018, The Journal of clinical investigation.

Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4

U. Gerdemann, C. Cruz, H. Heslop, 2011 .

Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

U. Gerdemann, C. Cruz, H. Heslop, 2011, Clinical Cancer Research.

Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multiantigen-Associated Specific Cytotoxic T Lymphocytes: A Phase I Study.

S. Darko, P. Hanley, C. Cruz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths.

C. Cruz, E. Shpall, C. Bollard, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma

C. Cruz, H. Heslop, C. Rooney, 2010, Leukemia & lymphoma.

Mycobacteria-Specific T Cells May Be Expanded From Healthy Donors and Are Near Absent in Primary Immunodeficiency Disorders

S. Holland, P. Hanley, C. Cruz, 2019, Front. Immunol..

Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood

P. Hanley, J. Blaney, C. Cruz, 2017, Molecular therapy. Methods & clinical development.

T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect

C. Cruz, C. Bollard, 2015, Haematologica.

T-Cell Immunotherapy for Cancer

C. Cruz, C. Bollard, 2015 .

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

P. Hanley, C. Cruz, C. Rooney, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Cancer Therapy : Preclinical See commentary by Rezvani , p . 6955 Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A 4

U. Gerdemann, C. Cruz, H. Heslop, 2011 .

Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances

C. Cruz, C. Bollard, L. McLaughlin, 2015, Therapeutic advances in hematology.

Identification of novel HLA-restricted preferentially expressed antigen in melanoma peptides to facilitate off-the-shelf tumor-associated antigen-specific T-cell therapies.

P. Hanley, C. Cruz, A. Barrett, 2021, Cytotherapy.

Gene Modification of Human Natural Killer Cells Using a Retroviral Vector.

C. Cruz, C. Bollard, E. Yvon, 2016, Methods in molecular biology.

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

G. Lucchini, J. Orange, A. Gennery, 2016, The Journal of allergy and clinical immunology.

Strategic self-limiting production of infectious HIV particles by CRISPR in permissive cells

C. Cruz, C. Bollard, K. Khalili, 2023, Molecular therapy. Nucleic acids.

Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell Transplantation.

C. Cruz, S. Lam, C. Bollard, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.